<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710875</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72.180-20</org_study_id>
    <nct_id>NCT04710875</nct_id>
  </id_info>
  <brief_title>The Role of Lactate in Lipolysis and Catabolism in Humans</brief_title>
  <acronym>LILACH</acronym>
  <official_title>The Role of Lactate in Lipolysis and Catabolism in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lactate may have anti-lipolytic effects when plasma concentrations of lactate reach levels&#xD;
      similar to those seen during high intensity exercise.&#xD;
&#xD;
      This study aims to investigate how lactate concentrations similar to those achieved during&#xD;
      high intensity exercise affects lipolysis in humans. In addition to this, to investigate how&#xD;
      increased lactate concentrations affects glucose- and amino acid metabolism.&#xD;
&#xD;
      8 healthy males will be included. Study participants will undergo two separate investigation&#xD;
      days that will be identical except for the interventions:&#xD;
&#xD;
        1. Intravenous sodium D/L-lactate&#xD;
&#xD;
        2. Intravenous sodium chloride.&#xD;
&#xD;
      The study consists of a 3-hour basal period followed by a 3-hour hyperinsulinemic euglycemic&#xD;
      clamp. During the study we will:&#xD;
&#xD;
        -  Estimate insulin sensitivity during the hyperinsulinemic euglycemic clamp (M value)&#xD;
&#xD;
        -  Use tracer kinetics to estimate lipid-, glucose and amino acid metabolism using&#xD;
           [9,10-3H]-palmitate, [3-3H]-glucose, [15N]-phenylalanine, [15N]-tyrosine, [2H4]-tyrosine&#xD;
           and [13C]-Urea.&#xD;
&#xD;
        -  Do muscle- and adipose tissue biopsies for analyses of signaling pathways involved in&#xD;
           regulation of lipid-, glucose and amino acid metabolism.&#xD;
&#xD;
        -  Do blood samples of relevant hormones, metabolites and cytokines.&#xD;
&#xD;
        -  Use indirect calorimetry to estimate study participants' resting energy expenditure and&#xD;
           respiratory quotient during the basal period.&#xD;
&#xD;
        -  Estimate cardiac ejection fraction by echocardiography and measure blood pressure during&#xD;
           both the basal- and clamp period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Metabolic effects of Na-lactate compared with NaCl on lipolysis</measure>
    <time_frame>2 hours (1 hour basal period, 1 hour clamp)</time_frame>
    <description>Change in [9,10-3H]-palmitate tracer flux</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Metabolic effects of Na-lactate compared with NaCl on glucose metabolism</measure>
    <time_frame>6 hours (3 hours basal period, 3 hours clamp)</time_frame>
    <description>Change in glucose metabolism quantified with [3-3H]-glucose tracer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>3 hours.</time_frame>
    <description>Hyperinsulinaemic euglycaemic clamp with 0.6mU/kg/min insulin and 20% glucose to calculate M value. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute metabolic effects of Na-lactate compared with NaCl on aminoacid metabolism</measure>
    <time_frame>6 hours</time_frame>
    <description>Change in aminoacid metabolism quantified with [15N]-phenylalanine, [15N]tyrosine, [2H4]tyrosine and [13C]-Urea tracers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect calorimetry during clamp</measure>
    <time_frame>20 minutes</time_frame>
    <description>Change in estimation of resting energy expenditure during clamp. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect calorimetry during basal conditions</measure>
    <time_frame>20 minutes</time_frame>
    <description>Change in estimation of respiratory quotient during basal period. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>15 minutes</time_frame>
    <description>Change in cardiac ejection fraction during basal period. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>15 minutes</time_frame>
    <description>Change in cardiac ejection fraction during clamp period. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>2 x 10 min</time_frame>
    <description>blood pressure (systolic and diastolic) during basal- and clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - Insulin</measure>
    <time_frame>6 hours.</time_frame>
    <description>Insulin concentrations. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - c-peptid</measure>
    <time_frame>6 hours.</time_frame>
    <description>c-peptid concentrations. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - glucagon</measure>
    <time_frame>6 hours.</time_frame>
    <description>glucagon concentrations. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - cortisol</measure>
    <time_frame>6 hours.</time_frame>
    <description>cortisol concentrations. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - Ghrelin</measure>
    <time_frame>6 hours.</time_frame>
    <description>Ghrelin concentrations. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - GDF-15</measure>
    <time_frame>6 hours.</time_frame>
    <description>GDF-15 concentrations. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - free fatte acids</measure>
    <time_frame>6 hours.</time_frame>
    <description>Free fatte acids concentrations. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - glucose</measure>
    <time_frame>6 hours.</time_frame>
    <description>glucose concentrations. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - lactate</measure>
    <time_frame>6 hours.</time_frame>
    <description>lactate concentrations. Difference between interventions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in signaling in muscle tissue between interventions</measure>
    <time_frame>After 3 and 5 hours of intervention</time_frame>
    <description>Western blot examinations of muscle tissue biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in signaling in adipose tissue between interventions</measure>
    <time_frame>After 3 and 5 hours of intervention</time_frame>
    <description>Western blot examinations of adipose tissue biopsies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Hyperlactatemia</condition>
  <condition>Healthy</condition>
  <condition>Lactate</condition>
  <arm_group>
    <arm_group_label>Na-lactate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Iv infusion of sodium D/L lactate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Iv infusion of Sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Na-lactate</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Na-lactate</arm_group_label>
    <other_name>Sodium lactate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <description>Intravenous</description>
    <arm_group_label>Sodium chloride</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male&#xD;
&#xD;
          -  &gt;18 years of age&#xD;
&#xD;
          -  BMI &gt;19 and below 30&#xD;
&#xD;
          -  Written and verbal consent to participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic illness&#xD;
&#xD;
          -  daily use of medicine&#xD;
&#xD;
          -  affected blood samples at screening, as assessed by the PI&#xD;
&#xD;
          -  does not speak and understand Danish&#xD;
&#xD;
          -  Assessed unsuitable by PI.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels MÃ¸ller, Prof, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Medical/Steno Aarhus research laboratory, Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical/Steno Aarhus research laboratory</name>
      <address>
        <city>Aarhus</city>
        <state>Central Region Denmark</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipolysis</keyword>
  <keyword>Catabolism</keyword>
  <keyword>Glucose metabolism</keyword>
  <keyword>Aminoacid metabolisme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlactatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

